India's Ipca acquires UK-based CMO Onyx Scientific; Carlyle reportedly in talks to buy PPD
Representing its first acquisition outside of India, Mumbai-based Ipca Laboratories has bought 100% of the share capital of Onyx Research Chemicals, the holding company for Onyx Scientific in a £4.6 million ($7.5 million) transaction.
The acquisition brings together two leading contract manufacturing organizations (CMOs) to better serve their customers on a global basis, the Indian firm stated. Onyx Scientific has been a premier chemistry solutions provider for over a decade and will continue to operate out of the Silverbriar (Sunderland, UK) facility under the Onyx Scientific trade name.
Ipca India provides CMO services through its Covenance business division. Onyx Scientific’s capabilities in chemistry services for medicinal, preclinical and Phase-I/II programs will dovetail effectively with Ipca’s capabilities in supporting Phase II to commercial scale programs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze